遺伝学的検査市場：疾患タイプ、技術、用途、エンドユーザー別-2025-2030年の世界予測

遺伝学的検査市場は、2023年に51億5,000万米ドルと評価され、2024年には55億7,000万米ドルに達すると予測され、CAGR 8.17％で成長し、2030年には89億3,000万米ドルになると予測されています。

遺伝子検査としても知られる遺伝学的検査は、DNAを分析して遺伝子、染色体、タンパク質の変化を特定し、遺伝性疾患の発見に役立てる。遺伝学的検査の範囲には、診断、予測、キャリア検査、出生前スクリーニング、新生児スクリーニングが含まれます。その必要性は、疾患の早期発見、個別化医療へのニーズの高まり、遺伝性疾患に対する一般市民の意識の高まりに後押しされています。この検査は、腫瘍学、心臓病学、神経学など様々な分野に応用され、ヘルスケア専門家、患者、研究者に提供されています。市場成長は主に、次世代シーケンシングのような技術的進歩、政府資金の増加、遺伝性疾患の有病率の上昇の影響を受けています。新興市場における個別化医療の拡大にはビジネスチャンスがあり、データ分析と解釈のためのAIの統合は検査の精度とスピードを高めることができます。こうした機会を捉えるための提言としては、検査の精度と価格を向上させるための研究開発への投資や、より広い範囲をカバーするためのヘルスケアプロバイダーとの協力関係の促進などがあります。

しかし、市場は規制上のハードル、遺伝子のプライバシーをめぐる倫理的懸念、潜在的な保険適用の制限などの課題に直面しています。これらの制限を克服するには、強固なデータプライバシー対策と倫理的懸念を和らげるための一般教育イニシアチブが必要です。革新的な成長分野としては、非侵襲的出生前検査、薬理ゲノミクスへの進出、消費者向け直接検査キットの開発などが挙げられます。市場は非常にダイナミックであり、競争の激化と急速な技術進歩によって特徴付けられ、継続的な革新と適応が必要とされます。企業は、戦略的パートナーシップやマーケティング・キャンペーンを通じて、手頃な価格と認知度の向上に注力する可能性があります。全体として、テクノロジーとヘルスケアの接点を活用することが、活況を呈する遺伝学的検査市場を活用する上で極めて重要であろう。

市場力学：急速に進化する遺伝学的検査市場の主要市場インサイトを公開

遺伝学的検査市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 潜在的な疾患の根本原因を見つけるためのDNAの変化や変異体の探索
  • 妊婦によるスクリーニングの増加
  • ゲノムシーケンスの研究開発活動の活発化
• 市場抑制要因
  • 限られた償還政策
• 市場機会
  • 共同製品開発
  • バリューチェーン内での魅力的な投資と合併活動
• 市場の課題
  • 遺伝学的検査の不確実な結果

ポーターの5つの力：遺伝学的検査市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、遺伝学的検査市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：遺伝学的検査市場における外部からの影響の把握

外部マクロ環境要因は、遺伝学的検査市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析遺伝学的検査市場における競合情勢の把握

遺伝学的検査市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス遺伝学的検査市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、遺伝学的検査市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨遺伝学的検査市場における成功への道筋を描く

遺伝学的検査市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品上市、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 潜在的な病気の根本原因を見つけるためにDNAの変化や変異を調査する
    • 妊婦のスクリーニング検査の増加
    • ゲノム配列解析の高度化に関する研究開発活動の活発化
  • 抑制要因
    • 限定的な払い戻しポリシー
  • 機会
    • 共同製品開発
    • バリューチェーン内の魅力的な投資と合併活動
  • 課題
    • 遺伝学的検査の不確実な結果
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 遺伝学的検査市場：疾患タイプ別

• 遺伝性がん検査
  • 乳がん
  • 子宮頸がん
  • 大腸がん
  • 肺がん
  • 悪性黒色腫
  • 卵巣がん
  • 膵臓がん
  • 前立腺がん
  • 肉腫
  • 胃がん
  • 子宮がん
• 遺伝性非がん検査
  • 遺伝子検査
    • 心臓疾患
    • 希少疾患
• 新生児遺伝子スクリーニング
• 非侵襲性出生前検査と保因者スクリーニング検査
• 着床前遺伝子診断とスクリーニング

第7章 遺伝学的検査市場：技術別

• 生化学的
• 細胞遺伝学的
• 分子検査

第8章 遺伝学的検査市場：用途別

• がんの診断
• 心血管疾患の診断
• 遺伝性疾患の診断

第9章 遺伝学的検査市場：エンドユーザー別

• クリニック
• 病院

第10章 南北アメリカの遺伝学的検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の遺伝学的検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの遺伝学的検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• BGI Genomics Co., Ltd.
• Biocartis NV
• CENTOGENE N.V.
• CooperSurgical, Inc.
• CSL Behring
• Eurofins Scientific SE
• F. Hoffmann-La Roche Ltd.
• Invitae Corporation
• Konica Minolta, Inc.
• Medgenome
• Myriad Genetics, Inc.
• Natera Inc.
• Quest Diagnostics Incorporated
• Siemens Healthineers AG
• SOPHiA Genetics

LIST OF FIGURES

• FIGURE 1. HEREDITARY TESTING MARKET RESEARCH PROCESS
• FIGURE 2. HEREDITARY TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HEREDITARY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HEREDITARY TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL HEREDITARY TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL HEREDITARY TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. HEREDITARY TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. HEREDITARY TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HEREDITARY TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HEREDITARY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL HEREDITARY TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. HEREDITARY TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL HEREDITARY TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL HEREDITARY TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL HEREDITARY TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL HEREDITARY TESTING MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL HEREDITARY TESTING MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL HEREDITARY TESTING MARKET SIZE, BY SARCOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL HEREDITARY TESTING MARKET SIZE, BY STOMACH OR GASTRIC CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL HEREDITARY TESTING MARKET SIZE, BY UTERINE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CARDIAC DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL HEREDITARY TESTING MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL HEREDITARY TESTING MARKET SIZE, BY NEWBORN GENETIC SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL HEREDITARY TESTING MARKET SIZE, BY NON-INVASIVE PRENATAL TESTING & CARRIER SCREENING TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS & SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL HEREDITARY TESTING MARKET SIZE, BY BIOCHEMICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CYTOGENETIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL HEREDITARY TESTING MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CANCER DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASE DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL HEREDITARY TESTING MARKET SIZE, BY GENETIC DISEASE DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 60. BRAZIL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. CANADA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 64. CANADA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 65. CANADA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 66. CANADA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 67. CANADA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 68. CANADA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. CANADA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 71. MEXICO HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 72. MEXICO HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 73. MEXICO HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 74. MEXICO HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 79. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 80. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 81. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 82. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 88. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 89. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 90. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 93. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 94. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 95. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 96. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 97. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 98. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. CHINA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 101. CHINA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 102. CHINA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 103. CHINA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 104. CHINA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 105. CHINA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. CHINA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. INDIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 108. INDIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 109. INDIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 110. INDIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 111. INDIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 112. INDIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. INDIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. INDONESIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 115. INDONESIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 116. INDONESIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 117. INDONESIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 118. INDONESIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 119. INDONESIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. INDONESIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. JAPAN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 122. JAPAN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 123. JAPAN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 124. JAPAN HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 125. JAPAN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 126. JAPAN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. JAPAN HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 129. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 130. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 131. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 132. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 133. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 136. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 137. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 138. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 139. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 140. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 143. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 144. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 145. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 146. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 147. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 150. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 151. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 152. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 153. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 154. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 155. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 156. TAIWAN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 157. TAIWAN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 158. TAIWAN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 159. TAIWAN HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 160. TAIWAN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 161. TAIWAN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 162. TAIWAN HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 163. THAILAND HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 164. THAILAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 165. THAILAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 166. THAILAND HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 167. THAILAND HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 168. THAILAND HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. THAILAND HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 170. VIETNAM HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 171. VIETNAM HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 172. VIETNAM HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 173. VIETNAM HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 174. VIETNAM HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 175. VIETNAM HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 176. VIETNAM HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 178. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 179. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 180. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 181. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 182. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 183. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 184. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 185. DENMARK HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 186. DENMARK HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 187. DENMARK HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 188. DENMARK HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 189. DENMARK HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 190. DENMARK HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 191. DENMARK HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 192. EGYPT HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 193. EGYPT HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 194. EGYPT HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 195. EGYPT HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 196. EGYPT HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 197. EGYPT HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 198. EGYPT HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 199. FINLAND HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 200. FINLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 201. FINLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 202. FINLAND HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 203. FINLAND HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 204. FINLAND HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 205. FINLAND HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 206. FRANCE HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 207. FRANCE HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 208. FRANCE HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 209. FRANCE HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 210. FRANCE HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 211. FRANCE HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 212. FRANCE HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 213. GERMANY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 214. GERMANY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 215. GERMANY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 216. GERMANY HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 217. GERMANY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 218. GERMANY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 219. GERMANY HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 220. ISRAEL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 221. ISRAEL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 222. ISRAEL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 223. ISRAEL HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 224. ISRAEL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 225. ISRAEL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 226. ISRAEL HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 227. ITALY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 228. ITALY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 229. ITALY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 230. ITALY HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 231. ITALY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 232. ITALY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 233. ITALY HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 234. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 235. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 236. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 237. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 238. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 239. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 240. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 241. NIGERIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 242. NIGERIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 243. NIGERIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 244. NIGERIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 245. NIGERIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 246. NIGERIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 247. NIGERIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 248. NORWAY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 249. NORWAY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 250. NORWAY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 251. NORWAY HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 252. NORWAY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 253. NORWAY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 254. NORWAY HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 255. POLAND HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 256. POLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 257. POLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 258. POLAND HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 259. POLAND HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 260. POLAND HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 261. POLAND HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 262. QATAR HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 263. QATAR HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 264. QATAR HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 265. QATAR HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 266. QATAR HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 267. QATAR HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 268. QATAR HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 269. RUSSIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 270. RUSSIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 271. RUSSIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 272. RUSSIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 273. RUSSIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 274. RUSSIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 275. RUSSIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 276. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 277. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 278. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 279. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 280. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 281. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 282. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 283. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 284. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 285. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 286. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 287. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 288. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 289. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 290. SPAIN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 291. SPAIN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 292. SPAIN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 293. SPAIN HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 294. SPAIN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 295. SPAIN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 296. SPAIN HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 297. SWEDEN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 298. SWEDEN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 299. SWEDEN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 300. SWEDEN HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 301. SWEDEN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 302. SWEDEN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 303. SWEDEN HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 304. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 305. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 306. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 307. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 308. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 309. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 310. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 311. TURKEY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 312. TURKEY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 313. TURKEY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 314. TURKEY HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 315. TURKEY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 316. TURKEY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 317. TURKEY HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 318. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 319. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 320. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 321. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 322. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 323. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 324. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 325. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 326. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 327. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
• TABLE 328. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
• TABLE 329. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 330. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 331. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 332. HEREDITARY TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 333. HEREDITARY TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Hereditary Testing Market was valued at USD 5.15 billion in 2023, expected to reach USD 5.57 billion in 2024, and is projected to grow at a CAGR of 8.17%, to USD 8.93 billion by 2030.

Hereditary testing, also known as genetic testing, involves analyzing DNA to identify changes in genes, chromosomes, or proteins, helping detect genetic disorders. The scope of hereditary testing encompasses diagnostic, predictive, and carrier testing, as well as prenatal and newborn screening. Its necessity is driven by the increasing need for early disease detection, personalized medicine, and growing public awareness about genetic disorders. It is applied in various areas, including oncology, cardiology, and neurology, catering to healthcare professionals, patients, and researchers. Market growth is primarily influenced by technological advancements like next-generation sequencing, increased government funding, and a rising prevalence of genetic diseases. Opportunities lie in expanding personalized medicine within emerging markets, and the integration of AI for data analysis and interpretation can enhance testing accuracy and speed. Recommendations to seize these opportunities include investing in R&D to improve test accuracy and affordability, and fostering collaborations with healthcare providers for wider reach.

However, the market faces challenges such as regulatory hurdles, ethical concerns surrounding genetic privacy, and potential insurance coverage limitations. Overcoming these limitations requires robust data privacy measures and public education initiatives to alleviate ethical concerns. Innovative areas for growth include non-invasive prenatal testing, expansion into pharmacogenomics, and the development of direct-to-consumer testing kits. The market is highly dynamic, characterized by increased competition and rapid technological advancements, necessitating continuous innovation and adaptation. Companies might focus on increasing affordability and awareness through strategic partnerships and marketing campaigns. Overall, leveraging the intersection of technology and healthcare will be crucial for capitalizing on the booming hereditary testing market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hereditary Testing Market

The Hereditary Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Exploration for changes or variants, in DNA to find root cause of potential disease
  • Increased screening by pregnant women
  • Rising R&D activities on advance Genome sequencing
• Market Restraints
  • Limited reimbursement policies
• Market Opportunities
  • Collaborative product development
  • Attractive investment and amalgamation activity within value chain
• Market Challenges
  • Uncertain outcomes of the hereditary testing

Porter's Five Forces: A Strategic Tool for Navigating the Hereditary Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hereditary Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hereditary Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hereditary Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hereditary Testing Market

A detailed market share analysis in the Hereditary Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hereditary Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hereditary Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hereditary Testing Market

A strategic analysis of the Hereditary Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hereditary Testing Market, highlighting leading vendors and their innovative profiles. These include BGI Genomics Co., Ltd., Biocartis NV, CENTOGENE N.V., CooperSurgical, Inc., CSL Behring, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., Invitae Corporation, Konica Minolta, Inc., Medgenome, Myriad Genetics, Inc., Natera Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG, and SOPHiA Genetics.

Market Segmentation & Coverage

This research report categorizes the Hereditary Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease Type, market is studied across Hereditary Cancer Testing, Hereditary Non-Cancer Testing, Newborn Genetic Screening, Non-Invasive Prenatal Testing & Carrier Screening Tests, and Preimplantation Genetic Diagnosis & Screening. The Hereditary Cancer Testing is further studied across Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma, Stomach or Gastric Cancer, and Uterine Cancer. The Hereditary Non-Cancer Testing is further studied across Genetic Tests. The Genetic Tests is further studied across Cardiac Diseases and Rare Diseases.
• Based on Technology, market is studied across Biochemical, Cytogenetic, and Molecular Testing.
• Based on Application, market is studied across Cancer Diagnosis, Cardiovascular Disease Diagnosis, and Genetic Disease Diagnosis.
• Based on End-User, market is studied across Clinics and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Exploration for changes or variants, in DNA to find root cause of potential disease
    • 5.1.1.2. Increased screening by pregnant women
    • 5.1.1.3. Rising R&D activities on advance Genome sequencing
  • 5.1.2. Restraints
    • 5.1.2.1. Limited reimbursement policies
  • 5.1.3. Opportunities
    • 5.1.3.1. Collaborative product development
    • 5.1.3.2. Attractive investment and amalgamation activity within value chain
  • 5.1.4. Challenges
    • 5.1.4.1. Uncertain outcomes of the hereditary testing
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Hereditary Testing Market, by Disease Type

• 6.1. Introduction
• 6.2. Hereditary Cancer Testing
  • 6.2.1. Breast Cancer
  • 6.2.2. Cervical Cancer
  • 6.2.3. Colorectal Cancer
  • 6.2.4. Lung Cancer
  • 6.2.5. Melanoma
  • 6.2.6. Ovarian Cancer
  • 6.2.7. Pancreatic Cancer
  • 6.2.8. Prostate Cancer
  • 6.2.9. Sarcoma
  • 6.2.10. Stomach or Gastric Cancer
  • 6.2.11. Uterine Cancer
• 6.3. Hereditary Non-Cancer Testing
  • 6.3.1. Genetic Tests
    • 6.3.1.1. Cardiac Diseases
    • 6.3.1.2. Rare Diseases
• 6.4. Newborn Genetic Screening
• 6.5. Non-Invasive Prenatal Testing & Carrier Screening Tests
• 6.6. Preimplantation Genetic Diagnosis & Screening

7. Hereditary Testing Market, by Technology

• 7.1. Introduction
• 7.2. Biochemical
• 7.3. Cytogenetic
• 7.4. Molecular Testing

8. Hereditary Testing Market, by Application

• 8.1. Introduction
• 8.2. Cancer Diagnosis
• 8.3. Cardiovascular Disease Diagnosis
• 8.4. Genetic Disease Diagnosis

9. Hereditary Testing Market, by End-User

• 9.1. Introduction
• 9.2. Clinics
• 9.3. Hospitals

10. Americas Hereditary Testing Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Hereditary Testing Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Hereditary Testing Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. BGI Genomics Co., Ltd.
• 2. Biocartis NV
• 3. CENTOGENE N.V.
• 4. CooperSurgical, Inc.
• 5. CSL Behring
• 6. Eurofins Scientific SE
• 7. F. Hoffmann-La Roche Ltd.
• 8. Invitae Corporation
• 9. Konica Minolta, Inc.
• 10. Medgenome
• 11. Myriad Genetics, Inc.
• 12. Natera Inc.
• 13. Quest Diagnostics Incorporated
• 14. Siemens Healthineers AG
• 15. SOPHiA Genetics